Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants to gather long-term safety data in long acting beta-2 adrenergic agonist asthma drugs.